|
Getting your Trinity Audio player ready...
|
The medical device sector in the healthcare industry has rapidly advanced in recent years due to its inherent innovation, and Catheter Precision Inc. (NYSE American: VTAK) stands out as a notable player in the healthcare electrophysiology sector. The company is renowned for its two key products: VIVO™, aiding in ventricular arrhythmia source detection pre-procedure, and LockeT, a closure retention device. Read Entire Summary Update Now!
Catheter Precision Inc. (NYSE American: VTAK) announced that Ronald Reagan UCLA Medical Center and Rady Children’s Hospital in San Diego, the University of California San Diego (UCSD) health system and HCA Healthcare Inc. (NYSE: HCA) all making initial purchases of their LockeT product. HCA Healthcare Inc., a leading provider of healthcare services in the United States, generating over $64 billion in revenue in 2023. It operates 186 hospitals and approximately 2,400 care sites across 20 states and throughout the United Kingdom. The potential inclusion of additional prestigious academic institutions in the near to mid-term should not be unexpected. Insider Financial Special Feature Read Now!
In Q1, the company expanded its sales team by adding several industry veterans. The expanded team aims to grow the marketing footprint into new markets and further penetrate existing ones. The company released the first-ever data on the preliminary clinical study of LockeT. In a study with 100 patients, there was 100% immediate hemostasis and same-day discharge. The study also showed LockeT’s effectiveness for wound closure up to 27F, reducing the need for multiple closure devices.
Active across these sectors, healthcare industry companies include: Mangoceuticals Inc (NASDAQ: MGRX), Biodexa Pharmaceuticals PLC-ADR (NASDAQ: BDRX), Citius Pharmaceuticals Inc (NASDAQ: CTXR), Novavax Inc (NASDAQ: NVAX), Ocugen Inc (NASDAQ: OCGN)
Related posts:
Catheter Precision (NYSE American: VTAK) Gaining Momentum as VIVO™ Innovative 3D Mapping System is Showcased
Bull Run 2024: Biopharma Healthcare Stocks Surge, Gaining Momentum: DYAI, ABVC, FWBI, VTAK, NEXI
Catheter Precision Inc (NYSE American: VTAK) Announces Q4 and FY23 Results and Authorizes CEO to Make “Open Market” Purchases of Company Shares
Healthcare Innovations and Collaborations Fuel Industry Expansion Stocks Under $1 Look Now! OCGN, VTAK, RSCI, VERU, AGEN
Catheter Precision Inc. (NYSE American: VTAK) Stock Surges Following LockeT Purchase Order from HCA Healthcare